Merck & Co to create a separate cancer unit as patent cliff looms

Merck & Co is restructuring by splitting its drug division into two separate businesses. The change is designed to spotlight its fastest-growing medicines as the blockbuster cancer therapy Keytruda nears patent expiration. The company plans to emphasize newer products, including a pneumonia vaccine and a treatment for lung disease, as key drivers of its next growth phase.